Uniphar (UPR) Share Price, News & Analysis

Company Overview

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Key Stats

• Today's Range: 334 to 344
• 50-Day Range: 311 to 352.60
• 52-Week Range: 163 to 368
• Volume: 10,472 shs
• Average Volume: 50,004 shs
• Market Capitalization: £882.55 million
• P/E Ratio: 1,387.76
• Dividend Yield: 0.01%
• Price Target: GBX 427.50
• Consensus Rating: Moderate Buy

UPR Stock Analysis - Frequently Asked Questions

How have UPR shares performed this year?

Uniphar's stock was trading at GBX 170.80 at the beginning of 2025. Since then, UPR shares have increased by 99.1% and is now trading at GBX 340.

How do I buy shares of Uniphar?

Shares of UPR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Uniphar own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Uniphar investors own include IXICO (IXI) and ANGLE (AGL).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: N/A
• Current Symbol: LON:UPR
• CIK: N/A
• Web: www.uniphar.ie
• Phone: 353 1 428 7777
• Fax: N/A
• Employees: 3,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Uniphar: GBX 427.50
• High Price Target: GBX 480
• Low Price Target: GBX 375
• Potential Upside/Downside: +25.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.25
• Trailing P/E Ratio: 1,387.76
• Forward P/E Ratio: 18.06
• P/E Growth: N/A
• Net Income: £51.04 million
• Net Margins: 1.68%
• Pretax Margin: N/A
• Return on Equity: 13.18%
• Return on Assets: 3.76%

Debt

• Debt-to-Equity Ratio: 119.48
• Current Ratio: 0.90
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: £2.89 billion
• Price / Sales: 0.31
• Cash Flow: GBX 34.12 per share
• Price / Cash Flow: 9.97
• Book Value: GBX 127.58 per share
• Price / Book: 2.66

Miscellaneous

• Outstanding Shares: 259,574,000
• Free Float: N/A
• Market Cap: £882.55 million
• Optionable: Not Optionable
• Beta: 0.75